David Reese, Amgen
Amgen spotlights preclinical 'multi-specifics' as analyst predicts late-stage M&A
If David Reese gets his way, Lumakras will be the first of many Amgen drugs that shatter the fences currently cordoning off vast swaths of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.